Tobinick v. Novella

207 F. Supp. 3d 1332, 44 Media L. Rep. (BNA) 2466, 2016 WL 4704945, 2016 U.S. Dist. LEXIS 121520
CourtDistrict Court, S.D. Florida
DecidedSeptember 8, 2016
DocketCASE NO. 9:14-cv-80781-ROSENBERG/BRANNON
StatusPublished
Cited by2 cases

This text of 207 F. Supp. 3d 1332 (Tobinick v. Novella) is published on Counsel Stack Legal Research, covering District Court, S.D. Florida primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Tobinick v. Novella, 207 F. Supp. 3d 1332, 44 Media L. Rep. (BNA) 2466, 2016 WL 4704945, 2016 U.S. Dist. LEXIS 121520 (S.D. Fla. 2016).

Opinion

ROBIN L. ROSENBERG, UNITED STATES DISTRICT JUDGE

ORDER GRANTING IN PART DEFENDANT NOVELLA’S OMNIBUS MOTION FOR ATTORNEYS’ FEES AND COSTS AND DENYING BONA AND GOTT’S MOTION FOR SANCTIONS

THIS CAUSE comes before the Court on Defendant Steven Novella, M.D.’s Omnibus Motion for Attorneys’ Fees and Costs [DE 292] and Jarod M. Bona and [1334]*1334Aaron R. Gott’s Motion for Sanctions under Federal Rule of Civil Procedure 11 [DE 320]. The Court has reviewed the motions, the responses and replies thereto, and all other relevant portions of the record. As more fully explained below, the Court finds that Novella is entitled to sanctions under the Anti-SLAPP statute and the Lanham Act. However, the Court reduces the amount of the fees sought under the Anti-SLAPP statute. The Court also finds that Novella is not entitled to sanctions under 28 U.S.C. § 1927.

I. PROCEDURAL HISTORY

A.Initial Claims and Parties

This lawsuit was initially filed in June 2014. The claims arose from two internet articles written by Defendant Dr. Steven Novella, which criticized Plaintiff Dr. Edward Lewis Tobinick’s use of a drug known as Enbrel to treat Alzheimer’s disease. Plaintiff Tobinick contended that these articles made false statements concerning the viability of the treatments, the scientific literature and testing that had been, conducted as to those treatments, the size and locations of Plaintiff Tobinick’s Institutes, and, by implication, the categorization of Plaintiff Tobinick’s practice as “health fraud.” These articles were published on a website called sciencebased-medicine.org.

The initial complaint brought claims under: (1) the Lanham Act, 15 U.S.C. § 1125(a); (2) unfair competition; (3) trade libel; (4) libel per se; and (5) tortious interference with business relationships. See DE 1 (Complaint); DE 55 (Amended Complaint). The listed Plaintiffs were Tobinick and related professional entities, and Defendants were Novella and the Society for Science-Based Medicine, Inc. (“the Society”), an organization owned by Novella that produces content for the seienceba-sedmedicine.org website.1

Both sides aggressively litigated this case from the outset. On June 11, 2014, Plaintiffs moved for a preliminary injunction. See DE 6. On August 18, 2014, the Society filed a motion to dismiss, which the Court later converted into a motion for summary judgment. See DE 74, 120. On September 30, 2014, Novella filed a special motion to strike the claims brought by Edward Lewis Tobinick, M.D., a California medical corporation, pursuant to California’s Anti-SLAPP Statute, California Code § 425.16. See DE 93.

B. Substitution of Counsel: Attorneys Cahen, Bona, and Gott begin representing Plaintiffs.

On January 28, 2015, shortly after the Court converted the Society’s motion to dismiss into a motion for summary judgment, Plaintiffs’ counsel withdrew and were replaced by attorneys from the law firm Broad and Cassel. See DE 126. In late February and early March 2015, counsel from Broad and Cassel withdrew and were replaced by Geoffrey M. Cahen of Cahen Law. P.A., Jarod Bona of Bona Law, P.C., and Aaron R. Gott of Bona Law, P.C. See DE 148, 149, 156.

C. Substitution of Counsel: Attorneys Cahen, Bona, and Gott begin representing Plaintiffs.

On March 16, 2015, following a hearing, the Court granted summary judgment for the Society. See DE 157. The Court found that the articles were not actionable under the Lanham Act or as unfair competition because “no reasonable jury could find the articles constitute commercial speech, at least with respect to the Society.” Id. at 12. The Court also noted: “[T]he targeted [1335]*1335entity, the Society, is a not-for-profit corporation. Like nearly every not-for-profit corporation, it seeks to support itself by soliciting donations and offering products for sale. That does not render its speech commercial, particularly where, as here, there is nothing in the record to indicate that the articles containing the allegedly false and/or defamatory statements do not remain free to view online.” Id. at 13.2

D.Order Denying Plaintiffs’ Motion for a Preliminary Injunction: The Court finds they are unlikely to prevail on the Lanham Act claims because the speech at issue is not commercial.

On April 2, 2016, following an evidentia-ry hearing, the Court denied Plaintiffs’ motion for preliminary injunction. See DE 172. The Court reasoned that Plaintiffs had failed to demonstrate a substantial likelihood of prevailing on the merits with respect to their Lanham Act claim, again finding that the speech at issue was not commercial. Id. at ¶¶ 3-13. The Court found that Plaintiffs had “failed to demonstrate that Dr. Novella has an economic motivation for the speech,” rejecting Plaintiffs’ contention that income from courses and podcasts related to the Society or from a legal defense fund set up in response to the lawsuit transformed the speech into commercial speech. Id. at ¶¶ 10-11. The Court noted, “[Sjcience communication is Dr. Novella’s passion, interest and hobby. No evidence was introduced to indicate that it is his primary source of income (or even, with respect to the Society and www.sciencebasedmedicine.org, a source of income at all), and the Court accordingly concludes that his motivation for authoring the articles was not economic in nature.” Id. at ¶ 12.3

E. Plaintiffs Seek Leave to File a Second Amended Complaint

About a month later, Plaintiffs moved for leave to file a second amended complaint. See E 173, 177. The amendment sought to add a claim for civil conspiracy under Florida common law, alleging that Defendants “agreed to embark on a campaign under which Defendants would act in concert to republish false statements alleged herein “in order to “promote the original ESA webpage, to raise the Defendants’ profiles within the skeptic community, and to drive web traffic, membership, and sale of merchandise on Defendants’ websites.” See DE 177-1 at ¶¶ 155-56 (Proposed Second Amended Complaint). The amendment also sought to add three Defendants: two new parties, Jay Novella and Paul Ingraham, and one previously-dismissed party, SGU Productions, LLC. Id. at 1.

Defendant Steven Novella opposed the amendment, see DE 188, and also moved for sanctions against Plaintiffs’ counsel under 28 U.S.C. § 1927, arguing counsel was unreasonably and vexatiously multiplying the proceedings. See DE 175. The Court denied the § 1927 motion without prejudice, finding the issues would be more suitably decided after the conclusion of the case. See DE 190.

F. Order Granting Defendant Novella’s Anti-SLAPP Motion: The Court finds no evidence that the statements were made with actual malice and that Novella is entitled to attorney’s fees and costs.

On June 4, 2015, while the motion to amend was pending, the Court issued an [1336]

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
207 F. Supp. 3d 1332, 44 Media L. Rep. (BNA) 2466, 2016 WL 4704945, 2016 U.S. Dist. LEXIS 121520, Counsel Stack Legal Research, https://law.counselstack.com/opinion/tobinick-v-novella-flsd-2016.